Last reviewed · How we verify
SoC chemotherapy treatment 2
SoC chemotherapy treatment 2 is a Small molecule drug developed by BioNTech SE. It is currently in Phase 1 development.
At a glance
| Generic name | SoC chemotherapy treatment 2 |
|---|---|
| Sponsor | BioNTech SE |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (PHASE3)
- Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma (PHASE2)
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SoC chemotherapy treatment 2 CI brief — competitive landscape report
- SoC chemotherapy treatment 2 updates RSS · CI watch RSS
- BioNTech SE portfolio CI
Frequently asked questions about SoC chemotherapy treatment 2
What is SoC chemotherapy treatment 2?
SoC chemotherapy treatment 2 is a Small molecule drug developed by BioNTech SE.
Who makes SoC chemotherapy treatment 2?
SoC chemotherapy treatment 2 is developed by BioNTech SE (see full BioNTech SE pipeline at /company/biontech-se).
What development phase is SoC chemotherapy treatment 2 in?
SoC chemotherapy treatment 2 is in Phase 1.
Related
- Manufacturer: BioNTech SE — full pipeline
- Compare: SoC chemotherapy treatment 2 vs similar drugs
- Pricing: SoC chemotherapy treatment 2 cost, discount & access